Previous 10 | Next 10 |
Gainers: Just Energy Group (NYSE: JE ) +35% . More news on: Just Energy Group Inc., Nutanix, Inc., FTS International, Inc., Stocks on the move, Read more ...
Due to demand, Oncternal Therapeutics' (NASDAQ: ONCT ) book runner H.C. Wainwright & Co. has agreed to increase the size of its previous offering to purchase ~2.14M shares of common stock (from 1.67M) at $2.10/share, for expected gross proceeds of ~$4.5M. More news on: Oncternal Th...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commi...
Oncternal Therapeutics (NASDAQ: ONCT ) inks securities purchase agreement with underwriter to offer 1.67M shares of common stock priced at $2.10 per share; underwriters' overallotment option is additional 250K shares. More news on: Oncternal Therapeutics, Inc., Healthcare stocks ...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purc...
Oncternal Therapeutics, Inc. (ONCT) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Richard Vincent – Chief Financial Officer Jim Breitmeyer – President & Chief Executive Officer Frank Hsu – Chief Medical Officer Confere...
- 58% complete response rate reported in patients with relapsed/refractory mantle cell lymphoma (MCL) in ongoing Phase 1/2 clinical trial of cirmtuzumab with ibrutinib, and the regimen was well tolerated. Meeting requested with FDA to discuss registration pathway for cirmtuzumab for patient...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2020 financial results after U.S. financial markets close on Thursday, August 6, 2020. Oncternal...
Call on Wednesday, July 29 th @ 1:30 p.m. Eastern Time; register here Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a call with a key opinion leader (K...
Gainers: Global Eagle Entertainment ENT +164% . More news on: Hamilton Beach Brands Holding Company, Wilhelmina International, Inc., Oncternal Therapeutics, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets c...
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...